L. Leinbach
University of Pennsylvania
5 Papers
16 Citations
L. Leinbach is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Lenalidomide & Fludarabine. The author has an hindex of 3, co-authored 5 publications.
Chat about Author
Papers
Phase II Trial of Lenalidomide - Dexamethasone - Rituximab In Relapsed or Refractory Indolent B-Cell or Mantle Cell Lymphomas Resistant to Rituximab
Tahamtan Ahmadi,Elise A. Chong,Amanda Gordon,L. Leinbach,Nicole A. Aqui,Sunita D. Nasta,Jakub Svoboda,Steven C. Goldstein,Stephen J. Schuster +8 more
TL;DR: Data indicate that the combination of continuous daily lenalidomide, low-dose weekly dexamethasone and rituximab combined with ritUXimab is effective in patients with indolent B-cell or mantle cell lymphomas previously resistant to ritukimab.
12
Adoptive immunotherapy with autologous CD3/CD28-costimulated T cells after fludarabine-based chemotherapy in patients with chronic lymphocytic leukemia.
Stephen J. Schuster,Chitra Hosing,Elizabeth J. Shpall,Bruce L. Levine,Nicole A. Aqui,Elise A. Chong,Jakub Svoboda,Amanda Gordon,John McMannis,Doyle Bosque,Julio Cotte,Andrea L. Brennan,Zhaohui Zheng,L. Leinbach,YinYan Xu,Elizabeth Veloso,William K. Decker,Catherine M. Bollard,Michael J. Keating,Carl H. June +19 more
TL;DR: ACTC results in a dose-independent acceleration of CD4+ cell recovery after fludarabine-based chemotherapy compared to historical controls, and significantly enhanced T-cell immunosynapse formation with autologous CLL.
3
Adoptive Immunotherapy with Autologous CD3/CD28-Costimulated T-Cells After Fludarabine-Based Chemotherapy in Patients with Chronic Lymphocytic Leukemia
Stephen J. Schuster,Chitra Hosing,Elizabeth J. Shpall,Bruce L. Levine,Nicole A. Aqui,Elise A. Chong,Jakub Svoboda,Amanda Gordon,John McMannis,Doyle Bosque,Julio Cotte,Andrea L. Brennan,Zhaohui Zheng,L. Leinbach,YinYan Xu,Elizabeth Veloso,William K. Decker,Catherine M. Bollard,Michael J. Keating,Carl H. June +19 more
TL;DR: A multicenter phase I/II trial of ACTC following fludarabine- or alemtuzumab-based therapy of CLL, finding that adoptive immunotherapy using autologous CD3/CD28-costimulated T-cells expanded ex vivo (ACTC) enhances immune reconstitution after fludARABine- based therapy of lymphoma.
1
Changes in regulatory T-cells in responding and non-responding patients with indolent B-cell or mantle cell lymphomas during treatment with lenalidomide, dexamethasone, and rituximab.
Nicole A. Aqui,L. Leinbach,Elise A. Chong,Tahamtan Ahmadi,Jakub Svoboda,Amanda Gordon,Lisa H. Downs,S. Nasta,Stephen J. Schuster +8 more
TL;DR: Lenalidomide may enhance anti-tumor immune responses by inhibiting regulatory T-cells (Tregs) and by augmenting NK-cell mediated antibody-dependent cytotoxicity when combined with rituximab.
1
CD25 Blockade Depletes and Selectively Reprograms Regulatory T Cells in Concert with Immunotherapy in Cancer Patients
Andrew J. Rech,Rosemarie Mick,Sunil Martin,Adri Recio,Nicole A. Aqui,Daniel J. Powell,Theresa A. Colligon,Jennifer A. Trosko,L. Leinbach,Charles H. Pletcher,Carol Kaplan Tweed,Angela DeMichele,Kevin Fox,Susan M. Domchek,James L. Riley,Robert H. Vonderheide +15 more
TL;DR: It is concluded that CD25 blockade depletes and selectively reprograms Tregs in concert with active immune therapy in cancer patients, suggesting a mechanism to target cancer-associated T Regs while avoiding autoimmunity.